{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:48:50Z","timestamp":1792900130165,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00405-024-09177-9","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T03:00:33Z","timestamp":1738378833000},"page":"2821-2832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of bevacizumab in hereditary hemorrhagic telangiectasia: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"282","author":[{"given":"Amira Mohamed","family":"Taha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5906-9852","authenticated-orcid":false,"given":"Areeba","family":"Fareed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Elewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Tarek","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9606-4196","authenticated-orcid":false,"given":"Toka","family":"Elboraay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Abouelmagd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6276-4992","authenticated-orcid":false,"given":"Marwa Muhammed","family":"Abdeljawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"key":"9177_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/MAJ.0b013e3182429866","volume":"343","author":"JM Fleagle","year":"2012","unstructured":"Fleagle JM, Bobba RK, Kardinal CG, Freter CE (2012) Iron Deficiency Anemia related to Hereditary Hemorrhagic Telangiectasia Response to Treatment with Bevacizumab. Am J Med Sci 343:249\u2013251. https:\/\/doi.org\/10.1097\/MAJ.0b013e3182429866","journal-title":"Am J Med Sci"},{"key":"9177_CR2","first-page":"818","volume":"90","author":"H Sadick","year":"2005","unstructured":"Sadick H, Riedel F, Naim R, Goessler U, H\u00f6rmann K, Hafner M et al (2005) Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 90:818\u2013828","journal-title":"Haematologica"},{"key":"9177_CR3","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1056\/NEJMc0901421","volume":"360","author":"P Bose","year":"2009","unstructured":"Bose P, Holter JL, Selby GB (2009) Bevacizumab in Hereditary Hemorrhagic Telangiectasia. N Engl J Med 360:2143\u20132144. https:\/\/doi.org\/10.1056\/NEJMc0901421","journal-title":"N Engl J Med"},{"key":"9177_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/jmg.2009.069013","volume":"48","author":"ME Faughnan","year":"2011","unstructured":"Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD et al (2011) International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 48:73\u201387. https:\/\/doi.org\/10.1136\/jmg.2009.069013","journal-title":"J Med Genet"},{"key":"9177_CR5","first-page":"157","volume":"17","author":"C Grigg","year":"2017","unstructured":"Grigg C, Anderson D, Earnshaw J (2017) Diagnosis and treatment of Hereditary Hemorrhagic Telangiectasia. Ochsner J 17:157\u2013161","journal-title":"Ochsner J"},{"key":"9177_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jpeds.2019.03.013","volume":"210","author":"AKC Leung","year":"2019","unstructured":"Leung AKC, Leong KF, Barankin B (2019) Hereditary Hemorrhagic Telangiectasia. J Pediatr 210:232. https:\/\/doi.org\/10.1016\/j.jpeds.2019.03.013","journal-title":"J Pediatr"},{"key":"9177_CR7","doi-asserted-by":"publisher","first-page":"1089847","DOI":"10.3389\/fphar.2023.1089847","volume":"14","author":"H Chen","year":"2023","unstructured":"Chen H, Zhang Z, Chen X, Wang C, Chen M, Liao H et al (2023) Meta-analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxis. Front Pharmacol 14:1089847. https:\/\/doi.org\/10.3389\/fphar.2023.1089847","journal-title":"Front Pharmacol"},{"key":"9177_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2500\/ajr.2007.21.2969","volume":"21","author":"JD Richmon","year":"2007","unstructured":"Richmon JD, Tian Y, Husseman J, Davidson TM (2007) Use of a Sprayed Fibrin Hemostatic Sealant after Laser Therapy for Hereditary Hemorrhagic Telangiectasia Epistaxis. Am J Rhinol 21:187\u2013191. https:\/\/doi.org\/10.2500\/ajr.2007.21.2969","journal-title":"Am J Rhinol"},{"key":"9177_CR9","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2500\/ajr.2008.22.3145","volume":"22","author":"RJ Harvey","year":"2008","unstructured":"Harvey RJ, Kanagalingam J, Lund VJ (2008) The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis. Am J Rhinol 22:182\u2013187. https:\/\/doi.org\/10.2500\/ajr.2008.22.3145","journal-title":"Am J Rhinol"},{"key":"9177_CR10","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1517\/14712598.2013.813478","volume":"13","author":"T Kanellopoulou","year":"2013","unstructured":"Kanellopoulou T, Alexopoulou A (2013) Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia. Expert Opin Biol Ther 13:1315\u20131323. https:\/\/doi.org\/10.1517\/14712598.2013.813478","journal-title":"Expert Opin Biol Ther"},{"key":"9177_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13023-019-1239-6","volume":"14","author":"H Al-Samkari","year":"2019","unstructured":"Al-Samkari H, Albitar HA, Olitsky SE, Clancy MS, Iyer VN (2019) Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia an international survey of HHT centers. Orphanet J Rare Dis 14:256. https:\/\/doi.org\/10.1186\/s13023-019-1239-6","journal-title":"Orphanet J Rare Dis"},{"key":"9177_CR12","doi-asserted-by":"publisher","first-page":"e0228486","DOI":"10.1371\/journal.pone.0228486","volume":"15","author":"C V\u00e1zquez","year":"2020","unstructured":"V\u00e1zquez C, Gonzalez ML, Ferraris A, Bandi JC, Serra MM (2020) Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia. PLoS ONE 15:e0228486. https:\/\/doi.org\/10.1371\/journal.pone.0228486","journal-title":"PLoS ONE"},{"key":"9177_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/lt.21417","volume":"14","author":"A Mitchell","year":"2008","unstructured":"Mitchell A, Adams LA, MacQuillan G, Tibballs J, vanden Driesen R, Delriviere L (2008) Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 14:210\u2013213. https:\/\/doi.org\/10.1002\/lt.21417","journal-title":"Liver Transpl"},{"key":"9177_CR14","doi-asserted-by":"publisher","unstructured":"Epperla N, Kapke JT, Karafin M, Friedman KD, Foy P (2016) Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding. Am J Hematol 91. https:\/\/doi.org\/10.1002\/ajh.24367","DOI":"10.1002\/ajh.24367"},{"key":"9177_CR15","doi-asserted-by":"publisher","first-page":"192","DOI":"10.5045\/br.2014.49.3.192","volume":"49","author":"JW Wee","year":"2014","unstructured":"Wee JW, Jeon YW, Eun JY, Kim HJ, Bae SB, Lee KT (2014) Hereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab. Blood Res 49:192\u2013195. https:\/\/doi.org\/10.5045\/br.2014.49.3.192","journal-title":"Blood Res"},{"key":"9177_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D (2009) Preferred reporting items for systematic reviews and Meta-analyses the PRISMA Statement. Ann Intern Med 151:264. https:\/\/doi.org\/10.7326\/0003-4819-151-4-200908180-00135","journal-title":"Ann Intern Med"},{"key":"9177_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"9177_CR18","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al (2011) The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928\u2013d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"9177_CR19","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jama.2016.11387","volume":"316","author":"S Dupuis-Girod","year":"2016","unstructured":"Dupuis-Girod S, Ambrun A, Decullier E, Fargeton A-E, Roux A, Br\u00e9ant V et al (2016) Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia A Randomized Clinical Trial. JAMA 316:934\u2013942. https:\/\/doi.org\/10.1001\/jama.2016.11387","journal-title":"JAMA"},{"key":"9177_CR20","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/hed.23655","volume":"37","author":"D Riss","year":"2015","unstructured":"Riss D, Burian M, Wolf A, Kranebitter V, Kaider A, Arnoldner C (2015) Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia a double-blind, randomized, placebo\u2010controlled trial. Head Neck 37:783\u2013787. https:\/\/doi.org\/10.1002\/hed.23655","journal-title":"Head Neck"},{"key":"9177_CR21","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/lary.20159","volume":"119","author":"J Simonds","year":"2009","unstructured":"Simonds J, Miller F, Mandel J, Davidson TM (2009) The effect of bevacizumab (avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 119:988\u2013992. https:\/\/doi.org\/10.1002\/lary.20159","journal-title":"Laryngoscope"},{"key":"9177_CR22","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1002\/lary.27147","volume":"128","author":"J Steineger","year":"2018","unstructured":"Steineger J, Osnes T, Heimdal K, Dheyauldeen S (2018) Long-term experience with intranasal bevacizumab therapy. Laryngoscope 128:2237\u20132244. https:\/\/doi.org\/10.1002\/lary.27147","journal-title":"Laryngoscope"},{"key":"9177_CR23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jama.2016.11724","volume":"316","author":"KJ Whitehead","year":"2016","unstructured":"Whitehead KJ, Sautter NB, McWilliams JP, Chakinala MM, Merlo CA, Johnson MH et al (2016) Effect of Topical Intranasal Therapy on Epistaxis frequency in patients with Hereditary Hemorrhagic Telangiectasia. JAMA 316:943. https:\/\/doi.org\/10.1001\/jama.2016.11724","journal-title":"JAMA"},{"key":"9177_CR24","doi-asserted-by":"publisher","unstructured":"Thompson AB, Ross DA, Berard P, Figueroa-Bodine J, Livada N, Richer SL (2014) Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia. Allergy Rhinol 5:ar.2014.5.0091. https:\/\/doi.org\/10.2500\/ar.2014.5.0091","DOI":"10.2500\/ar.2014.5.0091"},{"key":"9177_CR25","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1002\/lary.23303","volume":"122","author":"S Dheyauldeen","year":"2012","unstructured":"Dheyauldeen S, \u00d8stertun Geirdal A, Osnes T, Vartdal LS, Dollner R (2012) Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis effectiveness of an injection protocol based on the vascular anatomy of the nose. Laryngoscope 122:1210\u20131214. https:\/\/doi.org\/10.1002\/lary.23303","journal-title":"Laryngoscope"},{"key":"9177_CR26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/joim.13714","volume":"294","author":"S Dupuis-Girod","year":"2023","unstructured":"Dupuis-Girod S, Rivi\u00e8re S, Lavigne C, Fargeton A-EA, Gilbert-Dussardier B, Grobost V et al (2023) Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia a national, randomized multicenter trial. J Intern Med 294:761\u2013774. https:\/\/doi.org\/10.1111\/joim.13714","journal-title":"J Intern Med"},{"key":"9177_CR27","doi-asserted-by":"publisher","first-page":"e0188943","DOI":"10.1371\/journal.pone.0188943","volume":"12","author":"A Guilhem","year":"2017","unstructured":"Guilhem A, Fargeton A-E, Simon A-C, Duffau P, Harle J-R, Lavigne C et al (2017) Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT) a retrospective study of 46 patients. PLoS ONE 12:e0188943. https:\/\/doi.org\/10.1371\/journal.pone.0188943","journal-title":"PLoS ONE"},{"key":"9177_CR28","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/lary.23230","volume":"122","author":"R Guldmann","year":"2012","unstructured":"Guldmann R, Dupret A, Nivoix Y, Schultz P, Debry C (2012) Bevacizumab nasal spray noninvasive treatment of epistaxis in patients with Rendu-Osler disease. Laryngoscope 122:953\u2013955. https:\/\/doi.org\/10.1002\/lary.23230","journal-title":"Laryngoscope"},{"key":"9177_CR29","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.3324\/haematol.2020.261859","volume":"106","author":"H Al-Samkari","year":"2021","unstructured":"Al-Samkari H, Kasthuri RS, Parambil JG, Albitar HA, Almodallal YA, V\u00e1zquez C et al (2021) An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia the InHIBIT-Bleed study. Haematologica 106:2161\u20132169. https:\/\/doi.org\/10.3324\/haematol.2020.261859","journal-title":"Haematologica"},{"key":"9177_CR30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.mayocp.2017.11.013","volume":"93","author":"VN Iyer","year":"2018","unstructured":"Iyer VN, Apala DR, Pannu BS, Kotecha A, Brinjikji W, Leise MD et al (2018) Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia\u2013Related Epistaxis and gastrointestinal bleeding. Mayo Clin Proc 93:155\u2013166. https:\/\/doi.org\/10.1016\/j.mayocp.2017.11.013","journal-title":"Mayo Clin Proc"},{"key":"9177_CR31","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/lary.21415","volume":"121","author":"TT Karnezis","year":"2011","unstructured":"Karnezis TT, Davidson TM (2011) Efficacy of intranasal bevacizumab (avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 121:636\u2013638. https:\/\/doi.org\/10.1002\/lary.21415","journal-title":"Laryngoscope"},{"key":"9177_CR32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/lary.22501","volume":"122","author":"TT Karnezis","year":"2012","unstructured":"Karnezis TT, Davidson TM (2012) Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy. Laryngoscope 122:495\u2013497. https:\/\/doi.org\/10.1002\/lary.22501","journal-title":"Laryngoscope"},{"key":"9177_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/JRSM.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT (2021) Risk-of-bias VISualization (robvis) an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 12:55\u201361. https:\/\/doi.org\/10.1002\/JRSM.1411","journal-title":"Res Synth Methods"},{"key":"9177_CR34","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/sj.bjc.6605167","volume":"101","author":"JS Thompson Coon","year":"2009","unstructured":"Thompson Coon JS, Liu Z, Hoyle M, Rogers G, Green C, Moxham T et al (2009) Sunitinib and Bevacizumab for first-line treatment of metastatic renal cell carcinoma a systematic review and indirect comparison of clinical effectiveness. Br J Cancer 101:238\u2013243. https:\/\/doi.org\/10.1038\/sj.bjc.6605167","journal-title":"Br J Cancer"},{"key":"9177_CR35","doi-asserted-by":"publisher","unstructured":"Mukherji SK (2010) Bevacizumab (Avastin). Am J Neuroradiol 31:235\u20136. https:\/\/doi.org\/10.3174\/ajnr.A1987","DOI":"10.3174\/ajnr.A1987"},{"key":"9177_CR36","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00277-006-0147-8","volume":"85","author":"D Flieger","year":"2006","unstructured":"Flieger D, Hainke S, Fischbach W (2006) Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 85:631\u2013632. https:\/\/doi.org\/10.1007\/s00277-006-0147-8","journal-title":"Ann Hematol"},{"key":"9177_CR37","doi-asserted-by":"publisher","first-page":"1001695","DOI":"10.3389\/fmed.2022.1001695","volume":"9","author":"H Yunus","year":"2022","unstructured":"Yunus H, Amin S, Haq FU, Ali W, Hamid T, Ali W et al (2022) Case report diagnosis of hereditary hemorrhagic telangiectasia (Osler Weber Rendu Syndrome) in a 23-year-old male presented with anemia and thrombocytopenia and its response to bevacizumab. Front Med 9:1001695. https:\/\/doi.org\/10.3389\/fmed.2022.1001695","journal-title":"Front Med"},{"key":"9177_CR38","doi-asserted-by":"publisher","first-page":"e24517","DOI":"10.7759\/cureus.24517","volume":"14","author":"AR Khan","year":"2022","unstructured":"Khan AR, Waqar S, Wazir MH, Arif A (2022) A rare case of Hereditary Hemorrhagic Telangiectasia A Case Report. Cureus 14:e24517. https:\/\/doi.org\/10.7759\/cureus.24517","journal-title":"Cureus"},{"key":"9177_CR39","doi-asserted-by":"publisher","unstructured":"Masood M, Coles M, Sifuentes H (2021) Management of refractory gastrointestinal bleeding in hereditary hemorrhagic telangiectasia with bevacizumab. Case Rep Gastrointest Med 2021:2242178. https:\/\/doi.org\/10.1155\/2021\/2242178","DOI":"10.1155\/2021\/2242178"},{"key":"9177_CR40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/joim.12832","volume":"285","author":"H Al-Samkari","year":"2019","unstructured":"Al-Samkari H, Kritharis A, Rodriguez-Lopez JM, Kuter DJ (2019) Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. J Intern Med 285:223\u2013231. https:\/\/doi.org\/10.1111\/joim.12832","journal-title":"J Intern Med"},{"key":"9177_CR41","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00405-011-1721-9","volume":"269","author":"C Rohrmeier","year":"2012","unstructured":"Rohrmeier C, Sachs HG, Kuehnel TS (2012) A retrospective analysis of low dose, intranasal injected bevacizumab (avastin) in hereditary haemorrhagic telangiectasia. Eur Arch Otorhinolaryngol 269:531\u2013536. https:\/\/doi.org\/10.1007\/s00405-011-1721-9","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"9177_CR42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4193\/rhino17.166","volume":"56","author":"P Stokes","year":"2017","unstructured":"Stokes P, Rimmer J (2017) Intranasal bevacizumab in the treatment of HHT -related epistaxis a systematic review. Rhinol J 56:3\u201310. https:\/\/doi.org\/10.4193\/rhino17.166","journal-title":"Rhinol J"},{"key":"9177_CR43","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/1945892418768588","volume":"32","author":"AA Halderman","year":"2018","unstructured":"Halderman AA, Ryan MW, Marple BF, Sindwani R, Reh DD, Poetker DM (2018) Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia an evidence-based review. Am J Rhinol Allergy 32:258\u2013268. https:\/\/doi.org\/10.1177\/1945892418768588","journal-title":"Am J Rhinol Allergy"},{"key":"9177_CR44","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.amjoto.2011.07.012","volume":"33","author":"BT Brinkerhoff","year":"2012","unstructured":"Brinkerhoff BT, Choong NW, Treisman JS, Poetker DM (2012) Intravenous and topical intranasal bevacizumab (avastin) in hereditary hemorrhagic telangiectasia. Am J Otolaryngol 33:349\u2013351. https:\/\/doi.org\/10.1016\/j.amjoto.2011.07.012","journal-title":"Am J Otolaryngol"},{"key":"9177_CR45","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00508-016-1124-4","volume":"129","author":"F Huemer","year":"2017","unstructured":"Huemer F, Dejaco M, Grabmer C, Melchardt T, Neureiter D, Mayer G et al (2017) Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia. Wien Klin Wochenschr 129:141\u2013144. https:\/\/doi.org\/10.1007\/s00508-016-1124-4","journal-title":"Wien Klin Wochenschr"},{"key":"9177_CR46","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1182\/bloodadvances.2024012589","volume":"8","author":"D Wang","year":"2024","unstructured":"Wang D, Ito S, Waldron C, Butt A, Zhang E, Krumholz HM et al (2024) Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia. Blood Adv 8:2835\u20132845. https:\/\/doi.org\/10.1182\/bloodadvances.2024012589","journal-title":"Blood Adv"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-09177-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-024-09177-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-09177-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:02:22Z","timestamp":1763413342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-024-09177-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["9177"],"URL":"https:\/\/doi.org\/10.1007\/s00405-024-09177-9","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"assertion":[{"value":"20 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}